ATLASTM, Genocea’s T cell antigen discovery platform, uniquely identifies surface-presented antigens of anti-tumor T cell responses and antigens of pro-tumor responses (InhibigensTM).
Inhibigens may be a novel tumor resistance mechanism that generate deleterious, tolerizing immune responses against cancer and should be avoided from vaccines and immunotherapies.
Inhibigens are found in most cancer patients and the ratio of
Inhibigens to neoantigens appears to predict checkpoint inhibitor (CPI) immunotherapy outcomes